President and Chief Scientific Officer, Regeneron Pharmaceuticals
Appears in 1 story
Leading Regeneron's scientific strategy and Dupixent expansion
Dupixent was approved for severe eczema in 2017 as a one-disease drug. Nine years later, it's approved for nine conditions, with the latest approval (February 24, 2026) covering allergic fungal rhinosinusitis (AFRS) — which previously had no approved treatment — and reducing the need for additional surgeries and steroid courses by 92% in trials.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
